What is the RYTM stock price?

Rhythm Pharmaceuticals, Inc. (RYTM) last available close: $86.44, as of 11/3/26. Prices on Cylvex may be delayed.

How many analyst price targets for RYTM were reached?

16 of 21 published price targets for RYTM were reached within 12 months (76% reached); 22 are still open. Counts only — firm names and target values are shown to signed-in members.

How many firms publish price targets or ratings on RYTM?

15 firms have published price targets or ratings on RYTM that Cylvex tracks. Counts only — firm names and target values are shown to signed-in members.

Is this investment advice?

No. Cylvex is an educational and informational platform; nothing on this page is investment, financial or trading advice. Past analyst targets do not predict future results.

NASDAQ

Updated Nov 3, 7:59 PM ET

RYTM

Rhythm Pharmaceuticals, Inc.

$87.46CS band Caution

−$7.00 (7.49%) At close $86.44 · Today

☾After Hours +$1.02 (1.18%) Nov 3, 7:59 PM ET

About RYTM

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Cylvex Score

Caution

Multiple risk signals, limited coverage

Multi-factor score. Not a buy/sell signal.

Score history

Calibrating

Score history is calibrating — it appears once enough daily scores are recorded.

What goes into the score

6 axes · equal weight

AnalystWall Street consensus & target distance

GrowthEarnings growth trajectory

ProfitabilityROE, margins, cash generation

ValuationPE, PEG, price-to-book ratios

TechnicalsPrice momentum & 52-week position

RiskBeta, volatility, leverage

The Cylvex Score is a multi-factor summary for education. Not a buy/sell signal. Not investment advice.